14.43

0.35% 0.05

Amicus Therapeutics Inc (FOLD)

Overview News Price History Option Chain Financials Why FOLD Down? Discussions Forecast

Amicus Therapeutics Inc stock is traded at $14.43, with a volume of 10.97M. It is up +0.35% in the last 24 hours and up +0.63% over the past month. Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Previous Close:

$14.38

Open:

$14.37

24h Volume:

10.97M

Relative Volume:

1.07

Market Cap:

$4.53B

Revenue:

$634.21M

Net Income/Loss:

$-27.11M

P/E Ratio:

-163.05

EPS:

-0.0885

Net Cash Flow:

$29.85M

1W Performance:

+0.42%

1M Performance:

+0.63%

6M Performance:

+73.23%

1Y Performance:

+58.92%

1-Day Range:

$14.37

$14.43

1-Week Range:

$14.37

$14.43

52-Week Range:

$5.51

$14.43

Amicus Therapeutics Inc Stock (FOLD) Company Profile

Name

Amicus Therapeutics Inc

Sector

Healthcare (1110)

Industry

Biotechnology (621)

Phone

(609) 662-2000

Address

47 HULFISH STREET, PRINCETON, NJ

Employee

511

Twitter

@amicusrx1

Next Earnings Date

2024-11-06

Latest SEC Filings

FOLD's Discussions on Twitter

Compare FOLD vs VRTX, REGN, ALNY, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FOLD Amicus Therapeutics Inc	14.43	4.53B	634.21M	-27.11M	29.85M	-0.0885
VRTX Vertex Pharmaceuticals Inc	454.00	115.33B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	732.87	77.48B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	312.17	41.40B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	663.93	41.09B	4.16B	1.29B	734.26M	19.59
ONC Beone Medicines Ltd Adr	275.28	30.56B	5.36B	287.73M	924.18M	2.5229

Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-22-26	Downgrade	Jefferies	Buy → Hold
Dec-29-25	Downgrade	Leerink Partners	Outperform → Market Perform
Dec-22-25	Downgrade	TD Cowen	Buy → Hold
Dec-17-25	Initiated	Citigroup	Buy
Sep-18-25	Upgrade	Needham	Hold → Buy
Jul-17-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-06-24	Initiated	Jefferies	Buy
May-30-24	Initiated	Wells Fargo	Overweight
May-14-24	Upgrade	Guggenheim	Neutral → Buy
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight
Apr-13-22	Resumed	Goldman	Neutral
Jan-14-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-15-21	Upgrade	Stifel	Hold → Buy
Sep-30-21	Upgrade	JP Morgan	Neutral → Overweight
Jul-19-21	Resumed	BTIG Research	Buy
May-27-21	Initiated	Needham	Hold
May-21-21	Initiated	UBS	Buy
Apr-14-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Mar-02-21	Initiated	Stifel	Hold
Feb-12-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-12-21	Downgrade	JP Morgan	Overweight → Neutral
Dec-28-20	Resumed	Cantor Fitzgerald	Overweight
Dec-10-20	Downgrade	Citigroup	Buy → Neutral
Nov-11-20	Initiated	Berenberg	Hold
Jun-17-20	Initiated	BTIG Research	Buy
Feb-04-20	Resumed	Cantor Fitzgerald	Overweight
Nov-12-19	Reiterated	H.C. Wainwright	Buy
Jun-17-19	Initiated	H.C. Wainwright	Buy
Jun-05-19	Reiterated	Cantor Fitzgerald	Overweight
Apr-05-19	Initiated	Janney	Buy
Jan-30-19	Initiated	Cantor Fitzgerald	Overweight
Oct-29-18	Initiated	Citigroup	Neutral
Aug-17-18	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-06-17	Resumed	Goldman	Neutral
Sep-13-17	Reiterated	Chardan Capital Markets	Buy
Aug-10-17	Reiterated	Chardan Capital Markets	Buy
Jan-24-17	Upgrade	Robert W. Baird	Neutral → Outperform
May-18-16	Initiated	BofA/Merrill	Buy
Apr-14-16	Initiated	Robert W. Baird	Neutral
Apr-12-16	Reiterated	Chardan Capital Markets	Buy
Sep-16-15	Downgrade	Chardan Capital Markets	Buy → Neutral
Jun-16-15	Reiterated	Chardan Capital Markets	Buy

View All

Amicus Therapeutics Inc Stock (FOLD) Latest News

Mar 20, 2026

Amicus Therapeutics stock hits 52-week high at 14.39 USD - Investing.com

Mar 20, 2026

Amicus Therapeutics stock hits 52-week high at 14.39 USD By Investing.com - Investing.com South Africa

Mar 20, 2026

Hudson Bay Capital Management LP Cuts Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat

Mar 20, 2026

Mar 17, 2026

Amicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week HighTime to Buy? - MarketBeat

Mar 17, 2026

FOLD Should I Buy - Intellectia AI

Mar 17, 2026

Mar 16, 2026

872,411 Shares in Amicus Therapeutics, Inc. $FOLD Acquired by Ion Asset Management Ltd. - MarketBeat

Mar 16, 2026

Iron Triangle Partners LP Takes Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat

Mar 16, 2026

BioMarin to acquire rare disease drug developer Amicus for $4.8B - MSN

Mar 16, 2026

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat

Mar 16, 2026

Mar 15, 2026

Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum And DCF Upside - Yahoo Finance

Mar 15, 2026

Amicus Therapeutics stock hits 52-week high at 14.38 USD By Investing.com - Investing.com Nigeria

Mar 15, 2026

Elevation Point Wealth Partners LLC Makes New Investment in Amicus Therapeutics, Inc. $FOLD - MarketBeat

Mar 15, 2026

Assessing Amicus Therapeutics (FOLD) Valuation After Strong Recent Share Price Momentum - simplywall.st

Mar 15, 2026

Mar 14, 2026